Industry Research Reports

Home > Reports > Pharma & Healthcare > Global and United States Mitochondrial-based Therapeutics Market Report & Forecast 2023-2029

Global and United States Mitochondrial-based Therapeutics Market Report & Forecast 2023-2029

Industry: Pharma & Healthcare

Published: 2023-03-24

Pages: 104 Pages

Report ld: 432873

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Mitochondria are therefore vital for normal cellular function, including intracellular metabolic activities and signal transduction of various cellular pathways. They are involved in cellular ion homeostasis, oxidative stress, and apoptotic and necrotic cell death.

Market Analysis and Insights: Global and United States Mitochondrial-based Therapeutics Market

This report focuses on global and United States Mitochondrial-based Therapeutics market, also covers the segmentation data of other regions in regional level and county level.

The global Mitochondrial-based Therapeutics revenue was US$ 379 million in 2022 and is forecast to a readjusted size of US$ 651.3 million by 2029 with a CAGR of 7.8% during the review period (2023-2029).

In United States the Mitochondrial-based Therapeutics revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period 2023-2029.

The global key players of Mitochondrial-based Therapeutics include Reneo Pharmaceutical, Pfizer Inc., Norvartis AG, Takeda Pharmaceuticals, Amgen Inc., NeuroVive Pharmaceutical AB, Entogene AG, Stealth Biotherapeutics and Ixchel Pharma, etc. The global five biggest players hold a share of % in 2022.

Global Mitochondrial-based Therapeutics Scope and Market Size
Mitochondrial-based Therapeutics market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Mitochondrial-based Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2029.

For United States market, this report focuses on the Mitochondrial-based Therapeutics market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in United States.

By Company
Reneo Pharmaceutical
Pfizer Inc.
Norvartis AG
Takeda Pharmaceuticals
Amgen Inc.
NeuroVive Pharmaceutical AB
Entogene AG
Stealth Biotherapeutics
Ixchel Pharma
Reata Pharmaceuticals

Segment by Type
Oral
Intravenous

Segment by Application
Mitochondrial Myopathy
Leber’s heredity Optic Neuropathy
Leigh Syndrome
Mitochondrial DNA Depletion Syndrome
Other

By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction
Chapter 1: Introduces Mitochondrial-based Therapeutics definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Detailed analysis of Mitochondrial-based Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5: Revenue of Mitochondrial-based Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6: Americas by type, by application and by country revenue for each segment.
Chapter 7: EMEA by type, by application and by region, revenue for each segment.
Chapter 8: China by type, by application revenue for each segment.
Chapter 9: APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Mitochondrial-based Therapeutics revenue, gross margin and recent development, etc.
Chapter 11: Analyst's Viewpoints/Conclusions

Table of Contents

 1 Study Coverage
    1.1 Mitochondrial-based Therapeutics Product Introduction
    1.2 Global Mitochondrial-based Therapeutics Outlook 2018 VS 2022 VS 2029
        1.2.1 Global Mitochondrial-based Therapeutics Market Size for the Year 2018-2029
        1.2.2 United States Mitochondrial-based Therapeutics Market Size for the Year 2018-2029
    1.3 Mitochondrial-based Therapeutics Market Size, United States VS Global, 2018 VS 2022 VS 2029
        1.3.1 The Market Share of United States Mitochondrial-based Therapeutics in Global, 2018 VS 2022 VS 2029
        1.3.2 The Growth Rate of Mitochondrial-based Therapeutics Market Size, United States VS Global, 2018 VS 2022 VS 2029
    1.4 Mitochondrial-based Therapeutics Market Dynamics
        1.4.1 Mitochondrial-based Therapeutics Industry Trends
        1.4.2 Mitochondrial-based Therapeutics Market Drivers
        1.4.3 Mitochondrial-based Therapeutics Market Challenges
        1.4.4 Mitochondrial-based Therapeutics Market Restraints
    1.5 Assumptions and Limitations
    1.6 Study Objectives
    1.7 Years Considered

 2 Mitochondrial-based Therapeutics by Type
    2.1 Mitochondrial-based Therapeutics Market Segment by Type
        2.1.1 Oral
        2.1.2 Intravenous
    2.2 Global Mitochondrial-based Therapeutics Market Size by Type (2018, 2022 & 2029)
    2.3 Global Mitochondrial-based Therapeutics Market Size by Type (2018-2029)
    2.4 United States Mitochondrial-based Therapeutics Market Size by Type (2018, 2022 & 2029)
    2.5 United States Mitochondrial-based Therapeutics Market Size by Type (2018-2029)

 3 Mitochondrial-based Therapeutics by Application
    3.1 Mitochondrial-based Therapeutics Market Segment by Application
        3.1.1 Mitochondrial Myopathy
        3.1.2 Leber’s heredity Optic Neuropathy
        3.1.3 Leigh Syndrome
        3.1.4 Mitochondrial DNA Depletion Syndrome
        3.1.5 Other
    3.2 Global Mitochondrial-based Therapeutics Market Size by Application (2018, 2022 & 2029)
    3.3 Global Mitochondrial-based Therapeutics Market Size by Application (2018-2029)
    3.4 United States Mitochondrial-based Therapeutics Market Size by Application (2018, 2022 & 2029)
    3.5 United States Mitochondrial-based Therapeutics Market Size by Application (2018-2029)

 4 Global Mitochondrial-based Therapeutics Competitor Landscape by Company
    4.1 Global Mitochondrial-based Therapeutics Market Size by Company
        4.1.1 Global Key Companies of Mitochondrial-based Therapeutics, Ranked by Revenue (2022)
        4.1.2 Global Mitochondrial-based Therapeutics Revenue by Player (2018-2023)
    4.2 Global Mitochondrial-based Therapeutics Concentration Ratio (CR)
        4.2.1 Mitochondrial-based Therapeutics Market Concentration Ratio (CR) (2018-2023)
        4.2.2 Global Top 5 and Top 10 Largest Companies of Mitochondrial-based Therapeutics in 2022
        4.2.3 Global Mitochondrial-based Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Key Players of Mitochondrial-based Therapeutics Head office and Area Served
    4.4 Global Key Players of Mitochondrial-based Therapeutics, Product and Application
    4.5 Global Key Players of Mitochondrial-based Therapeutics, Date of Enter into This Industry
    4.6 Companies Mergers & Acquisitions, Expansion Plans
    4.7 United States Mitochondrial-based Therapeutics Market Size by Company
        4.7.1 Key Players of Mitochondrial-based Therapeutics in United States, Ranked by Revenue (2022)
        4.7.2 United States Mitochondrial-based Therapeutics Revenue by Players (2021, 2022 & 2023)

 5 Global Mitochondrial-based Therapeutics Market Size by Region
    5.1 Global Mitochondrial-based Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
    5.2 Global Mitochondrial-based Therapeutics Market Size by Region (2018-2029)
        5.2.1 Global Mitochondrial-based Therapeutics Market Size by Region: 2018-2023
        5.2.2 Global Mitochondrial-based Therapeutics Market Size by Region (2024-2029)

 6 Americas
    6.1 Americas Mitochondrial-based Therapeutics Market Size YoY Growth 2018-2029
    6.2 Americas Mitochondrial-based Therapeutics Market Size by Type
        6.2.1 Americas Mitochondrial-based Therapeutics Market Size by Type (2018-2023)
        6.2.2 Americas Mitochondrial-based Therapeutics Market Size by Type (2024-2029)
        6.2.3 Americas Mitochondrial-based Therapeutics Market Share by Type (2018-2029)
    6.3 Americas Mitochondrial-based Therapeutics Market Size by Application
        6.3.1 Americas Mitochondrial-based Therapeutics Market Size by Application (2018-2023)
        6.3.2 Americas Mitochondrial-based Therapeutics Market Size by Application (2024-2029)
        6.3.3 Americas Mitochondrial-based Therapeutics Market Share by Application (2018-2029)
    6.4 Americas Mitochondrial-based Therapeutics Market Facts & Figures by Country (2018, 2022 & 2029)
        6.4.1 United States
        6.4.2 Canada
        6.4.3 Mexico
        6.4.4 Brazil

 7 EMEA
    7.1 EMEA Mitochondrial-based Therapeutics Market Size YoY Growth 2018-2029
    7.2 EMEA Mitochondrial-based Therapeutics Market Size by Type
        7.2.1 EMEA Mitochondrial-based Therapeutics Market Size by Type (2018-2023)
        7.2.2 EMEA Mitochondrial-based Therapeutics Market Size by Type (2024-2029)
        7.2.3 EMEA Mitochondrial-based Therapeutics Market Share by Type (2018-2029)
    7.3 EMEA Mitochondrial-based Therapeutics Market Size by Application
        7.3.1 EMEA Mitochondrial-based Therapeutics Market Size by Application (2018-2023)
        7.3.2 EMEA Mitochondrial-based Therapeutics Market Size by Application (2024-2029)
        7.3.3 EMEA Mitochondrial-based Therapeutics Market Share by Application (2018-2029)
    7.4 EMEA Mitochondrial-based Therapeutics Market Facts & Figures by Country (2018, 2022 & 2029)
        7.4.1 Europe
        7.4.2 Middle East
        7.4.3 Africa

 8 China
    8.1 China Mitochondrial-based Therapeutics Market Size YoY Growth 2018-2029
    8.2 China Mitochondrial-based Therapeutics Market Size by Type
        8.2.1 China Mitochondrial-based Therapeutics Market Size by Type (2018-2023)
        8.2.2 China Mitochondrial-based Therapeutics Market Size by Type (2024-2029)
        8.2.3 China Mitochondrial-based Therapeutics Market Share by Type (2018-2029)
    8.3 China Mitochondrial-based Therapeutics Market Size by Application
        8.3.1 China Mitochondrial-based Therapeutics Market Size by Application (2018-2023)
        8.3.2 China Mitochondrial-based Therapeutics Market Size by Application (2024-2029)
        8.3.3 China Mitochondrial-based Therapeutics Market Share by Application (2018-2029)

 9 APAC (excluding China)
    9.1 APAC Mitochondrial-based Therapeutics Market Size YoY Growth 2018-2029
    9.2 APAC Mitochondrial-based Therapeutics Market Size by Type
        9.2.1 APAC Mitochondrial-based Therapeutics Market Size by Type (2018-2023)
        9.2.2 APAC Mitochondrial-based Therapeutics Market Size by Type (2024-2029)
        9.2.3 APAC Mitochondrial-based Therapeutics Market Share by Type (2018-2029)
    9.3 APAC Mitochondrial-based Therapeutics Market Size by Application
        9.3.1 APAC Mitochondrial-based Therapeutics Market Size by Application (2018-2023)
        9.3.2 APAC Mitochondrial-based Therapeutics Market Size by Application (2024-2029)
        9.3.3 APAC Mitochondrial-based Therapeutics Market Share by Application (2018-2029)
    9.4 APAC Mitochondrial-based Therapeutics Market Facts & Figures by Country (2018, 2022 & 2029)
        9.4.1 Japan
        9.4.2 South Korea
        9.4.3 China Taiwan
        9.4.4 Southeast Asia
        9.4.5 India

 10 Key Players Profiles
    10.1 Reneo Pharmaceutical
        10.1.1 Reneo Pharmaceutical Company Details
        10.1.2 Reneo Pharmaceutical Business Overview
        10.1.3 Reneo Pharmaceutical Mitochondrial-based Therapeutics Introduction
        10.1.4 Reneo Pharmaceutical Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        10.1.5 Reneo Pharmaceutical Recent Development
    10.2 Pfizer Inc.
        10.2.1 Pfizer Inc. Company Details
        10.2.2 Pfizer Inc. Business Overview
        10.2.3 Pfizer Inc. Mitochondrial-based Therapeutics Introduction
        10.2.4 Pfizer Inc. Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        10.2.5 Pfizer Inc. Recent Development
    10.3 Norvartis AG
        10.3.1 Norvartis AG Company Details
        10.3.2 Norvartis AG Business Overview
        10.3.3 Norvartis AG Mitochondrial-based Therapeutics Introduction
        10.3.4 Norvartis AG Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        10.3.5 Norvartis AG Recent Development
    10.4 Takeda Pharmaceuticals
        10.4.1 Takeda Pharmaceuticals Company Details
        10.4.2 Takeda Pharmaceuticals Business Overview
        10.4.3 Takeda Pharmaceuticals Mitochondrial-based Therapeutics Introduction
        10.4.4 Takeda Pharmaceuticals Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        10.4.5 Takeda Pharmaceuticals Recent Development
    10.5 Amgen Inc.
        10.5.1 Amgen Inc. Company Details
        10.5.2 Amgen Inc. Business Overview
        10.5.3 Amgen Inc. Mitochondrial-based Therapeutics Introduction
        10.5.4 Amgen Inc. Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        10.5.5 Amgen Inc. Recent Development
    10.6 NeuroVive Pharmaceutical AB
        10.6.1 NeuroVive Pharmaceutical AB Company Details
        10.6.2 NeuroVive Pharmaceutical AB Business Overview
        10.6.3 NeuroVive Pharmaceutical AB Mitochondrial-based Therapeutics Introduction
        10.6.4 NeuroVive Pharmaceutical AB Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        10.6.5 NeuroVive Pharmaceutical AB Recent Development
    10.7 Entogene AG
        10.7.1 Entogene AG Company Details
        10.7.2 Entogene AG Business Overview
        10.7.3 Entogene AG Mitochondrial-based Therapeutics Introduction
        10.7.4 Entogene AG Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        10.7.5 Entogene AG Recent Development
    10.8 Stealth Biotherapeutics
        10.8.1 Stealth Biotherapeutics Company Details
        10.8.2 Stealth Biotherapeutics Business Overview
        10.8.3 Stealth Biotherapeutics Mitochondrial-based Therapeutics Introduction
        10.8.4 Stealth Biotherapeutics Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        10.8.5 Stealth Biotherapeutics Recent Development
    10.9 Ixchel Pharma
        10.9.1 Ixchel Pharma Company Details
        10.9.2 Ixchel Pharma Business Overview
        10.9.3 Ixchel Pharma Mitochondrial-based Therapeutics Introduction
        10.9.4 Ixchel Pharma Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        10.9.5 Ixchel Pharma Recent Development
    10.10 Reata Pharmaceuticals
        10.10.1 Reata Pharmaceuticals Company Details
        10.10.2 Reata Pharmaceuticals Business Overview
        10.10.3 Reata Pharmaceuticals Mitochondrial-based Therapeutics Introduction
        10.10.4 Reata Pharmaceuticals Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
        10.10.5 Reata Pharmaceuticals Recent Development

 11 Research Findings and Conclusion

 12 Appendix
    12.1 Research Methodology
        12.1.1 Methodology/Research Approach
        12.1.2 Data Source
    12.2 Disclaimer
    12.3 Author Details

Table of Figures

List of Tables
    Table 1. Mitochondrial-based Therapeutics Market Size United States VS Global, CAGR (2018 VS 2022 VS 2029)
    Table 2. Mitochondrial-based Therapeutics Market Trends
    Table 3. Mitochondrial-based Therapeutics Market Drivers
    Table 4. Mitochondrial-based Therapeutics Market Challenges
    Table 5. Mitochondrial-based Therapeutics Market Restraints
    Table 6. Global Mitochondrial-based Therapeutics Market Size by Type: 2018 VS 2022 VS 2029 (US$ Million)
    Table 7. United States Mitochondrial-based Therapeutics Market Size by Type: 2018 VS 2022 VS 2029 (US$ Million)
    Table 8. Global Mitochondrial-based Therapeutics Market Size by Application: 2018 VS 2022 VS 2029 (US$ Million)
    Table 9. United States Mitochondrial-based Therapeutics Market Size by Application: 2018 VS 2022 VS 2029 (US$ Million)
    Table 10. Global Key Companies of Mitochondrial-based Therapeutics, Ranked by Revenue (2022) & (US$ Million)
    Table 11. Global Mitochondrial-based Therapeutics Revenue by Player, (US$ Million), 2018-2023
    Table 12. Global Mitochondrial-based Therapeutics Revenue Share by Player, 2018-2023
    Table 13. Global Mitochondrial-based Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Mitochondrial-based Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mitochondrial-based Therapeutics as of 2022)
    Table 15. Global Key Players of Mitochondrial-based Therapeutics, Headquarters and Area Served
    Table 16. Global Key Players of Mitochondrial-based Therapeutics, Product and Application
    Table 17. Global Key Players of Mitochondrial-based Therapeutics, Date of Enter into This Industry
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Key Players of Mitochondrial-based Therapeutics in United States, Ranked by Revenue (2022) & (US$ Million)
    Table 20. United States Mitochondrial-based Therapeutics Revenue by Players, (US$ Million), 2021, 2022 & 2023
    Table 21. United States Mitochondrial-based Therapeutics Revenue Share by Players, 2021, 2022 & 2023
    Table 22. Global Mitochondrial-based Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 23. Global Mitochondrial-based Therapeutics Market Size by Region (2018-2023) & (US$ Million)
    Table 24. Global Mitochondrial-based Therapeutics Market Size Forecast by Region (2024-2029) & (US$ Million)
    Table 25. Americas Mitochondrial-based Therapeutics Market Size by Type (2018-2023) & (US$ Million)
    Table 26. Americas Mitochondrial-based Therapeutics Market Size by Type (2024-2029) & (US$ Million)
    Table 27. Americas Mitochondrial-based Therapeutics Market Size by Application (2018-2023) & (US$ Million)
    Table 28. Americas Mitochondrial-based Therapeutics Market Size by Application (2024-2029) & (US$ Million)
    Table 29. Americas Mitochondrial-based Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 30. Americas Mitochondrial-based Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 31. Americas Mitochondrial-based Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 32. EMEA Mitochondrial-based Therapeutics Market Size by Type (2018-2023) & (US$ Million)
    Table 33. EMEA Mitochondrial-based Therapeutics Market Size by Type (2024-2029) & (US$ Million)
    Table 34. EMEA Mitochondrial-based Therapeutics Market Size by Application (2018-2023) & (US$ Million)
    Table 35. EMEA Mitochondrial-based Therapeutics Market Size by Application (2024-2029) & (US$ Million)
    Table 36. EMEA Mitochondrial-based Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 37. EMEA Mitochondrial-based Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 38. EMEA Mitochondrial-based Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 39. China Mitochondrial-based Therapeutics Market Size by Type (2018-2023) & (US$ Million)
    Table 40. China Mitochondrial-based Therapeutics Market Size by Type (2024-2029) & (US$ Million)
    Table 41. China Mitochondrial-based Therapeutics Market Size by Application (2018-2023) & (US$ Million)
    Table 42. China Mitochondrial-based Therapeutics Market Size by Application (2024-2029) & (US$ Million)
    Table 43. China Mitochondrial-based Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 44. APAC Mitochondrial-based Therapeutics Market Size by Type (2018-2023) & (US$ Million)
    Table 45. APAC Mitochondrial-based Therapeutics Market Size by Type (2024-2029) & (US$ Million)
    Table 46. APAC Mitochondrial-based Therapeutics Market Size by Application (2018-2023) & (US$ Million)
    Table 47. APAC Mitochondrial-based Therapeutics Market Size by Application (2024-2029) & (US$ Million)
    Table 48. APAC Mitochondrial-based Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 49. APAC Mitochondrial-based Therapeutics Market Size by Region (2018-2023) & (US$ Million)
    Table 50. APAC Mitochondrial-based Therapeutics Market Size by Region (2024-2029) & (US$ Million)
    Table 51. Reneo Pharmaceutical Company Details
    Table 52. Reneo Pharmaceutical Business Overview
    Table 53. Reneo Pharmaceutical Mitochondrial-based Therapeutics Product
    Table 54. Reneo Pharmaceutical Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 55. Reneo Pharmaceutical Recent Development
    Table 56. Pfizer Inc. Company Details
    Table 57. Pfizer Inc. Business Overview
    Table 58. Pfizer Inc. Mitochondrial-based Therapeutics Product
    Table 59. Pfizer Inc. Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 60. Pfizer Inc. Recent Development
    Table 61. Norvartis AG Company Details
    Table 62. Norvartis AG Business Overview
    Table 63. Norvartis AG Mitochondrial-based Therapeutics Product
    Table 64. Norvartis AG Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 65. Norvartis AG Recent Development
    Table 66. Takeda Pharmaceuticals Company Details
    Table 67. Takeda Pharmaceuticals Business Overview
    Table 68. Takeda Pharmaceuticals Mitochondrial-based Therapeutics Product
    Table 69. Takeda Pharmaceuticals Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 70. Takeda Pharmaceuticals Recent Development
    Table 71. Amgen Inc. Company Details
    Table 72. Amgen Inc. Business Overview
    Table 73. Amgen Inc. Mitochondrial-based Therapeutics Product
    Table 74. Amgen Inc. Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 75. Amgen Inc. Recent Development
    Table 76. NeuroVive Pharmaceutical AB Company Details
    Table 77. NeuroVive Pharmaceutical AB Business Overview
    Table 78. NeuroVive Pharmaceutical AB Mitochondrial-based Therapeutics Product
    Table 79. NeuroVive Pharmaceutical AB Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 80. NeuroVive Pharmaceutical AB Recent Development
    Table 81. Entogene AG Company Details
    Table 82. Entogene AG Business Overview
    Table 83. Entogene AG Mitochondrial-based Therapeutics Product
    Table 84. Entogene AG Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 85. Entogene AG Recent Development
    Table 86. Stealth Biotherapeutics Company Details
    Table 87. Stealth Biotherapeutics Business Overview
    Table 88. Stealth Biotherapeutics Mitochondrial-based Therapeutics Product
    Table 89. Stealth Biotherapeutics Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 90. Stealth Biotherapeutics Recent Development
    Table 91. Ixchel Pharma Company Details
    Table 92. Ixchel Pharma Business Overview
    Table 93. Ixchel Pharma Mitochondrial-based Therapeutics Product
    Table 94. Ixchel Pharma Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 95. Ixchel Pharma Recent Development
    Table 96. Reata Pharmaceuticals Company Details
    Table 97. Reata Pharmaceuticals Business Overview
    Table 98. Reata Pharmaceuticals Mitochondrial-based Therapeutics Product
    Table 99. Reata Pharmaceuticals Revenue in Mitochondrial-based Therapeutics Business (2018-2023) & (US$ Million)
    Table 100. Reata Pharmaceuticals Recent Development
    Table 101. Research Programs/Design for This Report
    Table 102. Key Data Information from Secondary Sources
    Table 103. Key Data Information from Primary Sources
List of Figures
    Figure 1. Mitochondrial-based Therapeutics Product Picture
    Figure 2. Global Mitochondrial-based Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 3. Global Mitochondrial-based Therapeutics Market Size 2018-2029 (US$ Million)
    Figure 4. United States Mitochondrial-based Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 5. United States Mitochondrial-based Therapeutics Market Size 2018-2029 (US$ Million)
    Figure 6. United States Mitochondrial-based Therapeutics Market Share in Global 2018-2029
    Figure 7. Mitochondrial-based Therapeutics Report Years Considered
    Figure 8. Product Picture of Oral
    Figure 9. Product Picture of Intravenous
    Figure 10. Global Mitochondrial-based Therapeutics Market Share by Type in 2022 & 2029
    Figure 11. Global Mitochondrial-based Therapeutics Market Size by Type (2018-2029) & (US$ Million)
    Figure 12. Global Mitochondrial-based Therapeutics Market Share by Type (2018-2029)
    Figure 13. United States Mitochondrial-based Therapeutics Market Share by Type in 2022 & 2029
    Figure 14. United States Mitochondrial-based Therapeutics Market Size by Type (2018-2029) & (US$ Million)
    Figure 15. United States Mitochondrial-based Therapeutics Market Share by Type (2018-2029)
    Figure 16. Product Picture of Mitochondrial Myopathy
    Figure 17. Product Picture of Leber’s heredity Optic Neuropathy
    Figure 18. Product Picture of Leigh Syndrome
    Figure 19. Product Picture of Mitochondrial DNA Depletion Syndrome
    Figure 20. Product Picture of Other
    Figure 21. Global Mitochondrial-based Therapeutics Market Share by Application in 2022 & 2029
    Figure 22. Global Mitochondrial-based Therapeutics Market Size by Application (2018-2029) & (US$ Million)
    Figure 23. Global Mitochondrial-based Therapeutics Market Share by Application (2018-2029)
    Figure 24. United States Mitochondrial-based Therapeutics Market Share by Application in 2022 & 2029
    Figure 25. United States Mitochondrial-based Therapeutics Market Size by Application (2018-2029) & (US$ Million)
    Figure 26. United States Mitochondrial-based Therapeutics Market Share by Application (2018-2029)
    Figure 27. The Top 5 and 10 Largest Companies of Mitochondrial-based Therapeutics in the World: Market Share by Mitochondrial-based Therapeutics Revenue in 2022
    Figure 28. Global Mitochondrial-based Therapeutics Market Size Market Share by Region: 2018 VS 2022 VS 2029
    Figure 29. Global Mitochondrial-based Therapeutics Market Share by Region (2018-2029)
    Figure 30. Americas Mitochondrial-based Therapeutics Market Size Growth Rate 2018-2029 (US$ Million)
    Figure 31. Americas Mitochondrial-based Therapeutics Market Share by Type (2018-2029)
    Figure 32. Americas Mitochondrial-based Therapeutics Market Share by Application (2018-2029)
    Figure 33. United States Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 34. Canada Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 35. Mexico Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 36. Brazil Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 37. EMEA Mitochondrial-based Therapeutics Market Size Growth Rate 2018-2029 (US$ Million)
    Figure 38. EMEA Mitochondrial-based Therapeutics Market Share by Type (2018-2029)
    Figure 39. EMEA Mitochondrial-based Therapeutics Market Share by Application (2018-2029)
    Figure 40. Europe Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 41. Middle East Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 42. Africa Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 43. China Mitochondrial-based Therapeutics Market Size Growth Rate 2018-2029 (US$ Million)
    Figure 44. China Mitochondrial-based Therapeutics Market Share by Type (2018-2029)
    Figure 45. China Mitochondrial-based Therapeutics Market Share by Application (2018-2029)
    Figure 46. APAC Mitochondrial-based Therapeutics Market Size Growth Rate 2018-2029 (US$ Million)
    Figure 47. APAC Mitochondrial-based Therapeutics Market Share by Type (2018-2029)
    Figure 48. APAC Mitochondrial-based Therapeutics Market Share by Application (2018-2029)
    Figure 49. Japan Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 50. South Korea Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 51. China Taiwan Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 52. Southeast Asia Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 53. India Mitochondrial-based Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 54. Reneo Pharmaceutical Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 55. Pfizer Inc. Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 56. Norvartis AG Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 57. Takeda Pharmaceuticals Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 58. Amgen Inc. Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 59. NeuroVive Pharmaceutical AB Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 60. Entogene AG Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 61. Stealth Biotherapeutics Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 62. Ixchel Pharma Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 63. Reata Pharmaceuticals Revenue Growth Rate in Mitochondrial-based Therapeutics Business (2018-2023)
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed

Description

Mitochondria are therefore vital for normal cellular function, including intracellular metabolic activities and signal transduction of various cellular pathways. They are involved in cellular ion homeostasis, oxidative stress, and apoptotic and necrotic cell death.

Market Analysis and Insights: Global and United States Mitochondrial-based Therapeutics Market

This report focuses on global and United States Mitochondrial-based Therapeutics market, also covers the segmentation data of other regions in regional level and county level.

In United States the Mitochondrial-based Therapeutics revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period 2023-2029.

By Company
Reneo Pharmaceutical
Pfizer Inc.
Norvartis AG
Takeda Pharmaceuticals
Amgen Inc.
NeuroVive Pharmaceutical AB
Entogene AG
Stealth Biotherapeutics
Ixchel Pharma
Reata Pharmaceuticals

Segment by Type
Oral
Intravenous

Segment by Application
Mitochondrial Myopathy
Leber’s heredity Optic Neuropathy
Leigh Syndrome
Mitochondrial DNA Depletion Syndrome
Other

By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Industry: Pharma & Healthcare

Published: 2023-03-24

Pages: 104 Pages

Report ld: 432873

Request Sample

Pre-Order Enquiry

CHOOSE LICENSE TYPE

Single User License

USD 4350.00

Multi Users License

USD 6525.00

Corporate Users License